ArticleAdvances in therapy2026
The PKD Daily: Development and Content Validation of a Hybrid Diary for Tracking Urinary Events in Adults with Autosomal Dominant Polycystic Kidney Disease (ADPKD).
Article in Advances in therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionFor patients with autosomal dominant polycystic kidney disease (ADPKD), the only approved treatment is tolvaptan, a twice-daily medication that works to slow kidney function decline. Patients on tolvaptan report a considerable burden related to the drug's aquaretic effects which can intensify immediately following a dose of the medication.
methodsA targeted literature review and individual concept elicitation (CE) interviews with nephrologists and adult patients with ADPKD taking tolvaptan were conducted to inform the development of a hybrid diary, programmed as a smartphone application. A sample of adults with ADPKD taking tolvaptan tested the diary for 7 days; a subset also participated in cognitive debriefing (CD) interviews. The diary was then revised and finalized.
resultsCE interviews confirmed the importance of tracking urinary frequency and urgency and timing of tolvaptan doses in real time. Results from the usability/feasibility test and CD interviews confirmed the understandability and relevance of the diary and provided critical insights to improve its content and functionality. The resulting PKD Daily includes two daily entries to report dose timing, overnight urination, and daily impacts of frequent/urgent urination; real-time entries to capture frequency/urgency of daytime urination; and reminders to encourage regular data entry.
conclusionOriginally developed for use in a clinical trial, the PKD Daily can also provide valuable information to clinicians and patients to support treatment decisions and inform dose selection in clinical practice, becoming a valuable part of a clinician's toolbox. Further, the development of the PKD Daily can serve as a case study for the successful creation of a hybrid diary.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.